TiumBio
TiumBio is a clinical-stage Korean biopharmaceutical company developing novel therapeutics for rare and incurable diseases — including TGF-β/VEGF dual inhibitors, oral GnRH antagonists, and hemophilia biologics — monetized via global out-licensing and co-development partnerships with MSD, Chiesi, Hansoh, BeiGene, and Daewon.
- Company typePublic
- Founded2016
- HeadquartersSeongnam, South Korea
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What TiumBio does
TiumBio (티움바이오), founded in 2016 and listed on KOSDAQ (ticker 321550) in 2019, is a clinical-stage Korean biopharmaceutical company developing novel therapeutics for rare and incurable diseases. Its pipeline is built on two proprietary platforms — a synthetic small molecule (NCE) platform and a biologic (NBP) platform — yielding four core assets: TU2218 (Tosposertib), a first-in-class TGF-β/VEGF dual inhibitor in Phase 1b/2a for head and neck cancer with positive ASCO 2026 combination data alongside Keytruda (75% response rate, 10.9-month median PFS in 1L patients); TU2670 (Merigolix), a best-in-class oral GnRH antagonist in Phase 2 for endometriosis and uterine fibroids (Phase 2a primary endpoint met May 2024); TU7710, a bypassing factor biologic for hemophilia A patients with neutralizing antibodies in Phase 1; and TU7918, a long-acting Factor IX therapy for hemophilia B. The company owns 67 patents and has secured International Nonproprietary Names for both lead candidates.
The business model is a licensing-and-co-development GTM rather than direct commercialization. TiumBio out-licenses territorial rights and engages in clinical combination collaborations with global pharmaceutical partners — MSD (Merck) for the Keytruda combination, BeiGene for the tislelizumab combination, Chiesi (2018 out-license), Hansoh Pharma (China rights to Merigolix, including ART expansion), and Daewon Pharmaceutical (Korea rights). Revenue is therefore composed of upfront payments, development and regulatory milestones, royalties, and Korean government grants (KDDF, Ministry of Health and Welfare, Ministry of SMEs and Startups, KIPO). The company is not yet generating product revenue. CEO Hun-taek Kim (PhD, Texas A&M; MBA, USC), credited with developing Korea's first recombinant hemophilia protein and prior FDA/EMA-approved drugs, leads the company with a ~30.56% ownership stake. As of Q1 2026, TiumBio held approximately 125B KRW in near-cash assets and 301B KRW in total FVPL financial assets, with an ongoing FDA Breakthrough Therapy Designation application preparation for Tosposertib serving as the primary near-term catalyst.
TiumBio firmographics
Firmographics- Name
- TiumBio
- Legal name
- (주)티움바이오
- Website
- https://tiumbio.com
- Company type
- Public
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- TiumBio is a clinical-stage Korean biopharmaceutical company developing novel therapeutics for rare and incurable diseases — including TGF-β/VEGF dual inhibitors, oral GnRH antagonists, and hemophilia biologics — monetized via global out-licensing and co-development partnerships with MSD, Chiesi, Hansoh, BeiGene, and Daewon.
- Ownership category
- akta.pro rank
TiumBio industry classification
Industry- Product category
- Rare Disease Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Hematology Specialty Pharmaceuticals (Non-malignant) (HLAIACAI)
- akta.pro secondary industry
- Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
Keywords
Where TiumBio is headquartered
LocationHeadquarters
- HQ city
- Seongnam
- HQ country
- South Korea
- HQ region
- Asia
Offices1 record
Markets served
TiumBio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Technology Licensing / License-out Revenue: TiumBio generates revenue through licensing agreements with global pharmaceutical companies for its pipeline assets. Revenue includes upfront payments, milestone payments tied to development and regulatory achievements, and royalties on product sales. Notable license-outs include TU2218 to Chiesi (2018) and TU2670 to Hansoh Pharma and Daewon Pharmaceutical.
- Government Research Grants: The company receives government funding from Korean agencies including KDDF (Korea Drug Development Fund), the Ministry of Health and Welfare, the Ministry of SMEs and Startups, and the Korean Intellectual Property Office to support pipeline R&D.
- Equity Financing: As a pre-commercial biopharma, TiumBio relies on equity raises including KOSDAQ IPO (2019), Series C (400B KRW, 2019), Series B (235B KRW, 2018), and Series A (120B KRW, 2017). The company is not yet generating product revenue.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels7 records
TiumBio product offering
Product offeringCore offering
TiumBio is a clinical-stage biopharmaceutical company that discovers and develops novel therapeutics for rare and intractable diseases through two proprietary platforms: a synthetic small molecule (NCE) platform and a biologic (NBP) platform. Its four clinical-stage assets are TU2218 (Tosposertib, dual TGF-β/VEGF inhibitor for immuno-oncology and fibrosis), TU2670 (Merigolix, oral GnRH antagonist for endometriosis and uterine fibroids), TU7710 (bypassing factor biologic for hemophilia A with inhibitors), and TU7918 (long-acting Factor IX for hemophilia B). The company is pre-commercial and monetizes its pipeline through global out-licensing, co-development collaborations, and milestone/royalty arrangements.
Product overview
TiumBio is a clinical-stage biopharmaceutical company developing a pipeline of novel drugs for rare and incurable diseases. The portfolio consists of four main drug candidates: TU2218 (Tosposertib) is a dual TGF-β/VEGF inhibitor being developed as an immuno-oncology drug and for fibrosis; TU2670 (Merigolix) is an oral GnRH antagonist for endometriosis and uterine fibroids; TU7710 is a bypassing agent biologic for hemophilia patients with neutralizing antibodies; and TU7918 is a long-acting B-type hemophilia treatment. The company operates in both synthetic small molecule drugs and biologics, with a strategy focused on rare diseases with high unmet medical needs.
Differentiator
Problem solved
Functional benefit
Products and services
- TU2218 (Tosposertib) Oral dual TGF-β/VEGF inhibitor being developed as an immuno-oncology agent and anti-fibrotic treatment. The dual mechanism simultaneously targets cancer cell proliferation and the immunosuppressive tumor microenvironment, and is being evaluated in combination with anti-PD-1 antibodies for recurrent/metastatic head & neck squamous cell carcinoma.
- TU2670 (Merigolix) Oral gonadotropin-releasing hormone (GnRH) antagonist being developed for the treatment of endometriosis and uterine fibroids. Designed to offer a best-in-class profile with improved safety and efficacy over existing injectable GnRH agonists and other oral GnRH antagonists.
- TU7710 Bypassing agent biologic therapy for hemophilia A patients who have developed neutralizing antibodies to standard factor replacement therapy, with extended half-life designed to reduce infusion frequency.
- TU7918
Quantifiable outcome
- 1L mPFS 10.9 months (vs. ~3.6 months for standard Keytruda monotherapy, ~5.5 months for Keytruda+chemo)
- +3 more outcomes
Companies that use TiumBio
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles1 record
TiumBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
TiumBio partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Hansoh Pharma (한소제약)coreHansoh Pharma obtained China clinical Phase 1 approval for Merigolix (TU2670, HS-10518) in November 2023. Hansoh is also pursuing ART (Assisted Reproductive Technology) indications for the compound, with clinical trial approvals expanding the development scope. TiumBio receives milestone payments and royalties.
- BeiGenecoreBeiGene signed a clinical collaboration with TiumBio in February 2022 to evaluate TU2218 with tislelizumab (BeiGene's anti-PD-1 antibody) in combination therapy for cancer treatment.
- MSD (Merck & Co.)coreMSD and TiumBio signed a joint clinical collaboration agreement in 2022 to evaluate TU2218 (Tosposertib) in combination with MSD's Keytruda (pembrolizumab) for the treatment of recurrent/metastatic head and neck squamous cell carcinoma. The ongoing Phase 1b/2a clinical trial is evaluating safety and efficacy of the combination therapy.
- Daewon Pharmaceutical (대원제약)coreTechnology transfer of Merigolix (TU2670) to Daewon Pharmaceutical in 2022 for the Korean market. Daewon successfully completed Phase 2 clinical trial for uterine fibroids, achieving the primary endpoint of statistically significant reduction in heavy menstrual bleeding.
- SK Plasma (SK플라즈마)minorTiumBio entered a strategic partnership with SK Plasma through a capital increase participation in 2021, forming a strategic business relationship in the Korean biopharmaceutical sector.
- Protium Science (프로티움 사이언스)coreTiumBio established Protium Science as a subsidiary in 2021 (classified as a CDAO - Contract Development and Manufacturing Organization) to support internal drug development capabilities and potentially provide services.
- ChiesicoreIn 2018, TiumBio out-licensed TU2218 (NCE401) for the treatment of lung disease to global pharmaceutical company Chiesi. This represented one of the company's major global licensing achievements prior to refocusing on oncology indications.
Scale indicators14 records
Recent moves7 records
Expansion highlights6 records
TiumBio competitors and assessment
Company assessmentBroad incumbents
- Yuhan Corporation: Established Korean pharmaceutical company with a broad drug development pipeline including novel small molecules and biologics. Comparable as a Korea-based pharma with similar therapeutic area exposure, though operating at significantly larger scale.
- MSD (Merck & Co.): Global pharmaceutical leader and TiumBio's clinical collaboration partner for Keytruda+TU2218 combination in head and neck cancer. Comparable as the dominant IO player whose strategy and commercial priorities shape the value ceiling of TiumBio's combination programs.
- Hanmi Pharmaceutical: Korean pharmaceutical company with an extensive pipeline of novel small molecules and biologics. Comparable to TiumBio in therapeutic area focus and Korean clinical-stage development model, but with broader pipeline scope and commercial revenue.
- BeiGene: Major China-headquartered global oncology company and TiumBio's clinical collaboration partner for tislelizumab+TU2218 combination. Comparable as an oncology-focused company with PD-1 IO franchise, providing context on combination partnership economics.
Direct peers
- Innovent Biologics: Chinese biopharmaceutical company with both small molecule (Tyvyt/PD-1) and biologic drug development platforms. Comparable to TiumBio's dual NCE+NBP platform strategy and similarly pursues global pharma collaborations.
- Hansoh Pharma: Chinese pharmaceutical company and TiumBio's licensee for Merigolix (TU2670/HS-10518) in China. Comparable as a clinical-stage partner advancing the same women's health asset, providing a relevant proxy for development pace and regulatory execution in the China market.
- Ascletis Pharma: China-based clinical-stage biopharmaceutical company developing therapeutics in oncology, viral hepatitis, and metabolic diseases. Comparable to TiumBio as an Asia-based clinical-stage biotech pursuing global out-licensing with similar therapeutic area breadth.
- Hutchmed: China-based clinical-stage biopharmaceutical company focused on oncology drug discovery and development. Comparable to TiumBio as an Asia-based clinical-stage oncology biotech pursuing global out-licensing deals with multinational pharma partners.
- LegoChem Biosciences: Korean clinical-stage biotechnology company developing antibody-drug conjugates and biologics platforms. Comparable to TiumBio as a Korean clinical-stage biotech leveraging proprietary biologic discovery platforms and out-licensing models.
Regional players
- JW Pharmaceutical: Korean pharmaceutical company developing therapeutics across oncology, women's health, and rare diseases. Comparable to TiumBio in therapeutic area overlap and Korean market focus, though with more mature commercial operations.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
TiumBio social profiles
Digital presenceTiumBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
TiumBio leadership team
Management profileNumber of profiles
Profiles7 records
TiumBio subsidiaries and ownership
Company hierarchySubsidiaries2 records
TiumBio funding detail
Funding detailFunding overview
Funding rounds5 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TiumBio M&A and investment
M&A and investmentM&A
Investments3 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TiumBio
What does TiumBio do?
TiumBio is a clinical-stage biopharmaceutical company that discovers and develops novel therapeutics for rare and intractable diseases through two proprietary platforms: a synthetic small molecule (NCE) platform and a biologic (NBP) platform. Its four clinical-stage assets are TU2218 (Tosposertib, dual TGF-β/VEGF inhibitor for immuno-oncology and fibrosis), TU2670 (Merigolix, oral GnRH antagonist for endometriosis and uterine fibroids), TU7710 (bypassing factor biologic for hemophilia A with inhibitors), and TU7918 (long-acting Factor IX for hemophilia B). The company is pre-commercial and monetizes its pipeline through global out-licensing, co-development collaborations, and milestone/royalty arrangements.
Is TiumBio a public or private company?
TiumBio is a public company. It is classified as public and is currently operating.
When was TiumBio founded?
TiumBio was founded in 2016. It employs 51 to 100 people.
Where is TiumBio based?
TiumBio is headquartered in Seongnam, South Korea, in the Asia region.
How does TiumBio make money?
Three revenue lines are on record. Technology Licensing / License-out Revenue is the primary driver. The others are government Research Grants and equity Financing.
Who are TiumBio's main competitors?
Broad incumbents on record are Yuhan Corporation, MSD (Merck & Co.), Hanmi Pharmaceutical and BeiGene. Direct peers are Innovent Biologics, Hansoh Pharma, Ascletis Pharma, Hutchmed and LegoChem Biosciences. JW Pharmaceutical is listed as a regional player.
Does TiumBio have an API?
No public API is recorded for TiumBio.
What industry is TiumBio in?
TiumBio's product category is Rare Disease Therapeutics. Its primary akta.pro industry code is HLAIACAI, Hematology Specialty Pharmaceuticals (Non-malignant), with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 325412 and its SIC code is 2834.